Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 12/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2657758 | 0.92 | LCK (0.48) | LCKBTKCYP17A1CYP1A2GABRG2 | |
| SCHEMBL2660780 | 0.90 | GABRG2 (0.42) | LCKBTKLMNAPARP1HTT | |
| SCHEMBL4922653 | 0.88 | GABRG2 (0.49) | LCKBTKCYP1A2LMNAPARP1 | |
| SCHEMBL2660637 | 0.87 | LMNA (0.38) | LCKBTKLMNAPARP1HTT | |
| SCHEMBL2655382 | 0.87 | LMNA (0.38) | LCKBTKLMNAPARP1HTT | |
| SCHEMBL4924422 | 0.87 | LCK (0.51) | LCKBTKCYP17A1CYP1A2 | |
| SCHEMBL2655841 | 0.86 | DHPS (0.40) | LCKBTKCYP1A2LMNAPARP1 | |
| SCHEMBL2661290 | 0.86 | GABRG2 (0.46) | LCKBTKLMNAPARP1HTT | |
| SCHEMBL4919219 | 0.85 | HTT (0.36) | LMNAPARP1HTTPARP2GABRG2 | |
| SCHEMBL4924455 | 0.85 | GABRG2 (0.36) | LCKBTKCYP1A2LMNAPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | claimed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | COMT, BACE1, BDNF | LCK 4253/4885BTK 2744/4885CYP17A1 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.